Overview

Cross-over Study of Coronary Risk Factors With a Polypill

Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación para la Investigación Biosanitaria del Principado de Asturias
Treatments:
Aspirin
Atorvastatin
Ramipril